 |
Fludarabine Dosage
This dosage information may not include all the information needed to use Fludarabine safely and effectively. See additional information for Fludarabine.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Chronic Lymphocytic Leukemia
IV:
25 mg/m2 IV once over 30 minutes for 5 days every 28 days. Following a maximal tumor response, 3 additional cycles are recommended.
Oral:
40 mg/m2 once daily for 5 days every 28 days
Fludarabine phosphate can be taken either on an empty stomach or with food. The tablets have to be swallowed whole with water; they should not be chewed or broken.
Usual Adult Dose for non-Hodgkin's Lymphoma
25 mg/m2/day for 5 days every 28 days
Usual Pediatric Dose for Malignant Disease
Solid tumors: 7 to 9 mg/m2 IV bolus followed by 20 to 27 mg/m2/day continuous IV infusion for 5 days
Usual Pediatric Dose for Leukemia
Acute leukemia: 10 mg/m2 IV once over 15 minutes followed by continuous IV infusion of 30.5 mg/m2/day for 5 days or 10.5 mg/m2 IV once over 15 minutes followed by continuous IV infusion of 30.5 mg/m2/day for 2 days followed by cytarabine.
Usual Pediatric Dose for Stem Cell Transplant Conditioning
Reduced-intensity conditioning regimen prior to allogenic hematopoietic stem cell transplantation: 30 mg/m2/day for 5 days
Renal Dose Adjustments
CrCl 30-70 mL/min/1.73 m2:
Reduce dose by 20% and monitor closely for toxicity
CrCl less than 30 mL/min/1.73 m2:
IV: Not recommended for use
Oral (adults): Administer 50% of dose.
Liver Dose Adjustments
Caution is recommended
Dose Adjustments
The recommended dose of fludarabine may depend on whether other cytotoxic agents are coadministered. Reference to specific protocols is recommended.
Delay or decrease doses in cases of hematologic or other serious toxicities. In case of hemolysis, treatment should be discontinued.
Neurotoxicity: Consider treatment delay or discontinuation
Precautions
Severe bone marrow suppression, notably anemia, thrombocytopenia and neutropenia have been associated with the use of fludarabine.
Dialysis
There are no data specifically regarding use in dialysis. However, the following guidelines should be noted:
CrCl less than 30 mL/min/1.73 m2:
IV: Not recommended for use
Oral (adults): Administer 50% of dose
Other Comments
It is recommended to monitor the CBC with differential, platelet count, AST, ALT, creatinine, serum albumin, and uric acid during therapy.
